NeuroOne to Participate at the Oppenheimer Medtech, Tools and Diagnostics Summit on May 26th, 2021
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced its participation in the Oppenheimer Medtech, Tools and Diagnostics Summit on May 26, 2021. The summit includes an on-demand presentation for registered participants and one-on-one meetings. NeuroOne focuses on minimally invasive solutions for neurological disorders, including epilepsy and Parkinson's disease. The company has received FDA clearance for its Evo cortical technology, developed in partnership with Mayo Clinic and WARF, and is committed to enhancing surgical care options.
- None.
- None.
EDEN PRAIRIE, Minn., May 19, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that management will participate in the upcoming investor conference:
Oppenheimer Medtech, Tools and Diagnostics Summit
- May 26, 2021 (On demand presentation for registered participants and available for 1x1 meetings)
https://www.oppenheimer.com/events/2021/medtech-day-conference.aspx
To schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .
On February 23, 2021, the Company announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne's Evo™ (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson's disease, epilepsy and pain management due to failed back surgery procedures.
View original content to download multimedia:http://www.prnewswire.com/news-releases/neuroone-to-participate-at-the-oppenheimer-medtech-tools-and-diagnostics-summit-on-may-26th-2021-301294364.html
SOURCE NeuroOne Medical Technologies Corporation
FAQ
When is NeuroOne participating in the Oppenheimer Medtech Summit?
What is NeuroOne's focus in medical technology?
What product did NeuroOne receive FDA clearance for?
What partnerships has NeuroOne established for its technology?
What milestone did NeuroOne achieve with Zimmer Biomet?
